Tag - ARPO

Developments

Aerpio reports positive topline results from Phase 2 glaucoma trial

Aerpio Pharma (NASDAQ:ARPO) reported positive topline results from its Phase 2 trial evaluating razuprotafib for the treatment of elevated intraocular pressure (IOP). The study enrolled 194 patients with elevated IOP...

December 14, 2020

Markets

BTIG starts Aerpio Pharma at buy: PT $4

BTIG launched coverage of Aerpio Pharmaceuticals (NASDAQ:ARPO) with a “buy” rating and $4 price target. The stock closed at $2 on Dec. 8. “Aerpio is marching forward with several clinical programs of its first-in-class...

December 9, 2020

Developments

Aerpio completes enrollment in Phase 2 glaucoma trial

Aerpio Pharma (NASDAQ:ARPO) completed enrollment in its Phase 2 trial evaluating razuprotafib for the treatment of elevated intraocular pressure (IOP). The study enrolled some 195 patients with elevated IOP associated...

September 15, 2020

Developments

Aerpio Pharma misses primary endpoint in Phase 2b diabetic retinopathy trial

Aerpio Pharmaceuticals (NASDAQ:ARPO) lead candidate, AKB-9778, failed to meet its primary endpoint in its Phase 2b trial for moderate-to-severe non-proliferative diabetic retinopathy (NPDR). Compared to placebo, twice...

March 19, 2019

Tag - ARPO

Aerpio reports positive topline results from Phase 2 glaucoma trial

BTIG starts Aerpio Pharma at buy: PT $4

Aerpio completes enrollment in Phase 2 glaucoma trial

Aerpio Pharma misses primary endpoint in Phase 2b diabetic retinopathy trial

General

More